Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2016. The document serves as a transaction notification regarding dealings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain general business updates or operational reports.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Transaction Type: Increase in notional interest in Ordinary Shares or American Depositary Shares (ADSs).
- Transaction Date: October 13, 2016.
- Share Price (Ordinary Shares): £16.9675.
- Share Price (ADSs): $42.0900.
- Volume Range: Transactions ranged from approximately 178 to 447 shares/units per individual.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine increases in notional shareholdings for specific executives resulting from dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described are mechanical increases in notional interest under the Company's Deferred Investment Award Programme following the dividend payment on October 13, 2016.
Important Facts for Investors
- Executive Activity: The filing discloses transactions for seven executives, including CEO Designate Ms. E. Walmsley, President of Global Pharmaceuticals Mr. S. A. Hussain, and President of Pharmaceuticals R&D Dr. P. J. T. Vallance.
- Transaction Nature: All reported transactions were increases in notional interest via dividend reinvestment, not open market purchases or sales.
- Instrument Types: Most transactions involved Ordinary Shares (ISIN: GB0009252882), while one transaction by Mr. B. McNamara involved ADSs (ISIN: US37733W1053).
- Limitations: This document is not a financial report; it does not contain earnings data, balance sheet figures, or strategic outlooks.